Free Trial
NASDAQ:NVCT

Nuvectis Pharma Q4 2023 Earnings Report

Nuvectis Pharma logo
$6.00 -0.17 (-2.76%)
Closing price 08/8/2025 04:00 PM Eastern
Extended Trading
$6.00 0.00 (-0.08%)
As of 08/8/2025 04:29 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Nuvectis Pharma EPS Results

Actual EPS
-$0.41
Consensus EPS
-$0.40
Beat/Miss
Missed by -$0.01
One Year Ago EPS
N/A

Nuvectis Pharma Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Nuvectis Pharma Announcement Details

Quarter
Q4 2023
Time
N/A
Conference Call Date
Tuesday, March 5, 2024
Conference Call Time
7:00AM ET

Nuvectis Pharma Earnings Headlines

Roth Capital Cuts Earnings Estimates for Nuvectis Pharma
Nuvectis (NVCT) Q2 Loss Widens 43%
The Coin That Could Define Trump’s Crypto Presidency
When Trump returned to office, one of his first moves was to tap PayPal’s former COO, David Sacks, as a top advisor on crypto and AI. That alone signaled a shift. But insiders close to D.C. aren’t just talking crypto policy—they’re quietly buying something most retail investors have missed. While the crowd chases Bitcoin to $150,000, Weiss Ratings expert Juan Villaverde believes a different coin—already backed by giants like Google, Visa, and PayPal—could soon become crypto’s “Third Giant.”
Roth Capital Reduces Earnings Estimates for Nuvectis Pharma
See More Nuvectis Pharma Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Nuvectis Pharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Nuvectis Pharma and other key companies, straight to your email.

About Nuvectis Pharma

Nuvectis Pharma (NASDAQ:NVCT), a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma. It is also developing NXP900, a small molecule drug candidate, which is in Phase 1a clinical trails that inhibits the Proto-oncogene c-Src and YES1 kinases. It has license agreement with the CRT Pioneer Fund for the NXP800 and any of related derivatives; and the University of Edinburgh for the NXP900 and any of associated derivatives. The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021. Nuvectis Pharma, Inc. was incorporated in 2020 and is based in Fort Lee, New Jersey.

View Nuvectis Pharma Profile

More Earnings Resources from MarketBeat